HUGE FSD Pharma
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2020
Commission File Number: 001-39152
FSD PHARMA INC.
(Translation of registrant's name into English)
First Canadian Place
100 King St W, Suite 3400
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
INCORPORATION BY REFERENCE
The Registrant's Material Change Report dated October 27, 2020, included as Exhibit 99.1 of this Form 6-K (Commission File No. 001-39152), furnished to the Commission on October 27, 2020, is incorporated by reference into the Registration Statement on Form F-10 (Commission File No. 333-236780) of the Registrant, FSD Pharma Inc.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
FSD Pharma Inc.
Date: October 28, 2020
By: /s/ Donal Carroll
Name: Donal Carroll
Title: Chief Financial Officer